Please provide your email address to receive an email when new articles are posted on . Up to 88% of sentinel lymph node biopsies (SNLB) return with a negative result. The DecisionDx-Melanoma test, ...
This new, blood-based test successfully identifies individuals with lymph node metastasis associated with high-risk T1 colorectal cancer and potentially could help people with non-high-risk ...
A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk ...
Scientists at City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, have developed a novel, noninvasive liquid biopsy test for detecting lymph node ...
A genetic test might spare lymph node biopsy surgery among melanoma patients. About 93% of people classified as low risk by ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...
DUARTE, Calif. -- For years, surgeons have operated on pancreatic cancer patients to remove what they thought was a localized tumor only to discover that the disease had spread to other, inoperable ...
Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) ...
SINGAPORE – Singapore researchers have managed to extend the lifespan of lymph nodes outside the body, allowing them to study how the immune system reacts to vaccines and immunotherapies. To do this, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback